With a San Antonio biotech firm’s test, your phlegm could help save you from cancer.
The screening method developed by bioAffinity Technologies Inc. uses AI-aided computer analysis of a patient’s phlegm in a test that can spot lung cancer in high-risk patients earlier than other diagnosis methods.
BioAffinity Technologies Inc. has reached a significant milestone on its march to market.
The San Antonio-based biotech’s core technology, CyPath Lung, a non-invasive, early-stage cancer detection test, will be added to the U.S. Federal Supply Schedule, a procurement system that provides the Veterans Health Administration and Military Health System access to breakthrough health care products.
bioAffinity Technologies News Update SAN ANTONIO, Texas (July 3, 2024) – We are pleased to share the latest updates from bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW) as we continue to accelerate the commercialization of CyPath® Lung, our noninvasive diagnostic test to aid in the early detection of lung cancer. CEO Maria Zannes Interview on Bloomberg TV bioAffinity Technologies […]
The latest move is a key step for an Alamo City company pursuing widespread adoption of its core technology. As published in the San Antonio Business Journal By: W. Scott Bailey – Senior Reporter, San Antonio Business Journal Nov. 6, 2023 San Antonio-based bioAffinity Technologies has taken another key step in the commercialization of its novel cancer detection […]
Sept. 26, 2023 As published in 360Dx By Greg Cima NEW YORK – bioAffinity has its eyes on expanding sales of its sputum-based lung cancer test nationwide through its recent acquisition of the pathology laboratory that had licensed and developed that technology into a laboratory-developed test. According to its CEO, a national launch of the […]
bioAffinity Technologies CEO Maria Zannes says the company has made a key hire May 4, 2023 As published in the San Antonio Business Journal By: W. Scott Bailey – Senior Reporter, San Antonio Business Journal BioAffinity Technologies Inc. has made a key change in its executive ranks, locking in Michael Dougherty as its new chief […]